{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T19:25:11Z","timestamp":1787081111823,"version":"build-2736575974"},"reference-count":88,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Respiratory mucosal vaccination can induce robust humoral and cellular immune responses, as well as effective mucosal immunity at the primary site of pathogen entry, and has been shown to provide superior protection against respiratory viral infections compared with traditional approaches. Among current vaccine technologies, mRNA vaccines offer unique advantages, including rapid development, flexible antigen design, and potent immunogenicity. However, efficient mucosal delivery of mRNA remains challenging due to biological barriers within the respiratory tract, including mucus clearance, limited cellular uptake, and instability during aerosolization. Furthermore, mRNA formulations intended for respiratory mucosal delivery require more stringent safety and tolerability profiles. Recent advances in nanoparticle engineering have accelerated the development of mRNA delivery systems optimized for respiratory mucosal immunization. This review aims to evaluate how nanoparticle engineering strategies can overcome respiratory mucosal barriers and improve the safety, stability, delivery efficiency, extrahepatic expression, and immunogenicity of mRNA vaccines and therapeutics. We summarize recent progress in engineered mRNA nanoparticle platforms for respiratory mucosal immunity, encompassing modified lipid nanoparticles (LNPs), polymer-based mRNA nanoparticles, and hybrid nanoparticle systems, including lipid-inorganic, polymeric hybrid, and lipid-extracellular vesicle (EV) nanoparticles. We further discuss optimization strategies for mucosal mRNA delivery, including the incorporation of appropriate adjuvants, the development of polyethylene glycol (PEG) alternatives, and advanced delivery approaches. Finally, we highlight current challenges and future directions for the rational design of next-generation mRNA nanoparticle platforms that can induce durable and broadly protective mucosal immunity against respiratory viral infections.<\/jats:p>","DOI":"10.3390\/vaccines14070596","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:43:14Z","timestamp":1783345394000},"page":"596","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Engineered mRNA Nanoparticle Platforms for Respiratory Mucosal Delivery"],"prefix":"10.3390","volume":"14","author":[{"given":"Rui","family":"Jin","sequence":"first","affiliation":[{"name":"Emory Institute for Drug Development, Emory University, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1561-4318","authenticated-orcid":false,"given":"Bao-Zhong","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wandi","family":"Zhu","sequence":"additional","affiliation":[{"name":"Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Centers for Disease Control and Prevention (CDC) (2026). Respiratory Virus Activity\u2014United States, 1 July 2024\u201330 June 2025. Morb. Mortal. Wkly. Rep. (MMWR), 75, 77\u201384.","DOI":"10.15585\/mmwr.mm7506a2"},{"key":"ref_2","unstructured":"Centers for Disease Control and Prevention (CDC) (2026, July 02). 2024\u20132025 Influenza Season Summary: Severity, Disease Burden, and Burden Prevented, Available online: https:\/\/www.cdc.gov\/flu-burden\/php\/data-vis-vac\/2024-2025-prevented.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014A new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41573-024-01042-y","article-title":"mRNA vaccines for infectious diseases\u2014Advances, challenges and opportunities","volume":"23","author":"Pardi","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12985-025-02880-x","article-title":"Correction: Revolutionizing immunization: A comprehensive review of mRNA vaccine technology and applications","volume":"22","author":"Leong","year":"2025","journal-title":"Virol. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41573-023-00827-x","article-title":"Tailor made: The art of therapeutic mRNA design","volume":"23","author":"Metkar","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41577-021-00599-8","article-title":"Publisher Correction: Mucosal vaccines\u2014Fortifying the frontiers","volume":"22","author":"Lavelle","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Russell, M.W., Moldoveanu, Z., Ogra, P.L., and Mestecky, J. (2020). Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.611337"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41392-024-02043-4","article-title":"Mucosal immune response in biology, disease prevention and treatment","volume":"10","author":"Zhou","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Zhang, M., Li, N., He, Y., Shi, T., and Jie, Z. (2022). Pulmonary resident memory T cells in respiratory virus infection and their inspiration on therapeutic strategies. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.943331"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"eadd3075","DOI":"10.1126\/sciimmunol.add3075","article-title":"Route of self-amplifying mRNA vaccination modulates the establishment of pulmonary resident memory CD8 and CD4 T cells","volume":"7","author":"Kunzli","year":"2022","journal-title":"Sci. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"eadd4853","DOI":"10.1126\/sciimmunol.add4853","article-title":"Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination","volume":"7","author":"Tang","year":"2022","journal-title":"Sci. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/s41551-021-00786-x","article-title":"Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs","volume":"5","author":"Lokugamage","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jconrel.2023.12.012","article-title":"Nebulised delivery of RNA formulations to the lungs: From aerosol to cytosol","volume":"366","author":"Neary","year":"2024","journal-title":"J. Control. Release"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2017.09.023","article-title":"The biology of mucus: Composition, synthesis and organization","volume":"124","author":"Bansil","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/s41565-023-01548-3","article-title":"Combinatorial development of nebulized mRNA delivery formulations for the lungs","volume":"19","author":"Jiang","year":"2024","journal-title":"Nat. Nanotechnol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.addr.2017.08.010","article-title":"PEGylation for enhancing nanoparticle diffusion in mucus","volume":"124","author":"Huckaby","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102547","DOI":"10.1016\/j.omtn.2025.102547","article-title":"Deconvolution of cargo delivery and immunogenicity following intranasal delivery of mRNA lipid nanoparticle vaccines","volume":"36","author":"Vu","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jconrel.2022.03.046","article-title":"The replacement of helper lipids with charged alternatives in lipid nanoparticles facilitates targeted mRNA delivery to the spleen and lungs","volume":"345","author":"LoPresti","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1021\/acs.nanolett.2c04479","article-title":"The Transcriptional Response to Lung-Targeting Lipid Nanoparticles in Vivo","volume":"23","author":"Radmand","year":"2023","journal-title":"Nano Lett."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2407383","DOI":"10.1002\/advs.202407383","article-title":"Muco-Penetrating Lipid Nanoparticles Having a Liquid Core for Enhanced Intranasal mRNA Delivery","volume":"12","author":"Maniyamgama","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jdermsci.2016.11.010","article-title":"Triolein reduces MMP-1 upregulation in dermal fibroblasts generated by ROS production in UVB-irradiated keratinocytes","volume":"85","author":"Leiros","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jcf.2022.08.005","article-title":"beta-sitosterol ameliorates inflammation and Pseudomonas aeruginosa lung infection in a mouse model","volume":"22","author":"Rossi","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9217","DOI":"10.1021\/acsnano.5b03876","article-title":"Impact of Surface Polyethylene Glycol (PEG) Density on Biodegradable Nanoparticle Transport in Mucus ex Vivo and Distribution in Vivo","volume":"9","author":"Xu","year":"2015","journal-title":"ACS Nano"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e1601556","DOI":"10.1126\/sciadv.1601556","article-title":"Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation","volume":"3","author":"Schneider","year":"2017","journal-title":"Sci. Adv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.addr.2017.07.015","article-title":"Beyond PEGylation: Alternative surface-modification of nanoparticles with mucus-inert biomaterials","volume":"124","author":"Khutoryanskiy","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"14792","DOI":"10.1021\/acsnano.2c05647","article-title":"Engineering Lipid Nanoparticles for Enhanced Intracellular Delivery of mRNA through Inhalation","volume":"16","author":"Kim","year":"2022","journal-title":"Acs Nano"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e2307801120","DOI":"10.1073\/pnas.2307801120","article-title":"Cationic cholesterol-dependent LNP delivery to lung stem cells, the liver, and heart","volume":"121","author":"Radmand","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"eadh1655","DOI":"10.1126\/sciadv.adh1655","article-title":"Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection","volume":"9","author":"Meyer","year":"2023","journal-title":"Sci. Adv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/s41565-025-01961-w","article-title":"Compact polyethylenimine-complexed mRNA vaccines","volume":"20","author":"Stahl","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"13808","DOI":"10.1002\/anie.201608450","article-title":"Polymer-Lipid Nanoparticles for Systemic Delivery of mRNA to the Lungs","volume":"55","author":"Kaczmarek","year":"2016","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e1805116","DOI":"10.1002\/adma.201805116","article-title":"Inhaled Nanoformulated mRNA Polyplexes for Protein Production in Lung Epithelium","volume":"31","author":"Patel","year":"2019","journal-title":"Adv. Mater."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41587-021-00822-w","article-title":"Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents","volume":"39","author":"Blanchard","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6449","DOI":"10.1021\/acs.nanolett.8b02917","article-title":"Optimization of a Degradable Polymer-Lipid Nanoparticle for Potent Systemic Delivery of mRNA to the Lung Endothelium and Immune Cells","volume":"18","author":"Kaczmarek","year":"2018","journal-title":"Nano Lett."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7835","DOI":"10.1021\/acsnano.4c14041","article-title":"Targeted Delivery of mRNA with Polymer-Lipid Nanoparticles for In Vivo Base Editing","volume":"19","author":"Chen","year":"2025","journal-title":"ACS Nano"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41563-022-01404-0","article-title":"Species-agnostic polymeric formulations for inhalable messenger RNA delivery to the lung","volume":"22","author":"Rotolo","year":"2023","journal-title":"Nat. Mater."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"eabk2855","DOI":"10.1126\/sciadv.abk2855","article-title":"High-throughput and high-content bioassay enables tuning of polyester nanoparticles for cellular uptake, endosomal escape, and systemic in vivo delivery of mRNA","volume":"8","author":"Rui","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e2301606120","DOI":"10.1073\/pnas.2301606120","article-title":"Biodegradable lipophilic polymeric mRNA nanoparticles for ligand-free targeting of splenic dendritic cells for cancer vaccination","volume":"120","author":"Karlsson","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"eabq0603","DOI":"10.1126\/scitranslmed.abq0603","article-title":"Polymer nanoparticles deliver mRNA to the lung for mucosal vaccination","volume":"15","author":"Suberi","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"eadt8637","DOI":"10.1126\/sciadv.adt8637","article-title":"Cellular determinants influence the red blood cell adsorption efficiency of poly(amine-co-ester) nanoparticles","volume":"11","author":"Binns","year":"2025","journal-title":"Sci. Adv."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2425986","DOI":"10.1002\/adfm.202425986","article-title":"Biodegradable Hyperbranched Poly(Amine-Co-Ester)-Based Polymeric Nanoparticles for mRNA Delivery","volume":"35","author":"Liu","year":"2025","journal-title":"Adv. Funct. Mater."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"eabc9396","DOI":"10.1126\/scitranslmed.abc9396","article-title":"An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates","volume":"12","author":"Erasmus","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"102595","DOI":"10.1016\/j.omtn.2025.102595","article-title":"Antigen-dependent interplay of formulation, systemic innate responses, and antibody responses to multi-component replicon RNA vaccination","volume":"36","author":"Kimura","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jconrel.2024.11.023","article-title":"Preclinical development of lyophilized self-replicating RNA vaccines for COVID-19 and malaria with improved long-term thermostability","volume":"377","author":"Gulati","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1208\/s12248-021-00611-y","article-title":"FDA\u2019s Poly (Lactic-Co-Glycolic Acid) Research Program and Regulatory Outcomes","volume":"23","author":"Wang","year":"2021","journal-title":"AAPS J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1096\/fj.02-0088com","article-title":"Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: Implications for drug and gene delivery","volume":"16","author":"Panyam","year":"2002","journal-title":"FASEB J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"100311","DOI":"10.1016\/j.celbio.2025.100311","article-title":"A hybrid polymeric system for pulmonary mRNA delivery: Advancing mucosal vaccine development","volume":"2","author":"Jiang","year":"2026","journal-title":"Cell Biomater."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jcis.2006.07.031","article-title":"Colloidal stability of pluronic F68-coated PLGA nanoparticles: A variety of stabilisation mechanisms","volume":"302","author":"Csaba","year":"2006","journal-title":"J. Colloid Interface Sci."},{"key":"ref_51","first-page":"1659","article-title":"Transcribed mRNA Delivery Using PLGA\/PEI Nanoparticles into Human Monocyte-derived Dendritic Cells","volume":"18","author":"Sharifnia","year":"2019","journal-title":"Iran. J. Pharm. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.biomaterials.2011.09.061","article-title":"Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors","volume":"33","author":"Zhou","year":"2012","journal-title":"Biomaterials"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s12195-018-0536-9","article-title":"Lipid Polymer Hybrid Nanomaterials for mRNA Delivery","volume":"11","author":"Zhao","year":"2018","journal-title":"Cell. Mol. Bioeng."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"114385","DOI":"10.1016\/j.jconrel.2025.114385","article-title":"Design of messenger RNA vaccines based on lipid-polymer hybrid nanoparticles","volume":"388","author":"Baghel","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"114755","DOI":"10.1016\/j.ejpb.2025.114755","article-title":"Lipid-Polyhydroxyalkanoate Hybrid Nanoparticles as Sustainable Platform for mRNA delivery","volume":"213","author":"Mazrad","year":"2025","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"E4133","DOI":"10.1073\/pnas.1600299113","article-title":"Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose","volume":"113","author":"Chahal","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1038\/s41467-025-56448-y","article-title":"Targeted delivery of TGF-beta mRNA to murine lung parenchyma using one-component ionizable amphiphilic Janus Dendrimers","volume":"16","author":"Meshanni","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1021\/acs.molpharmaceut.2c00738","article-title":"Poly(aspartic acid)-Based Polymeric Nanoparticle for Local and Systemic mRNA Delivery","volume":"19","author":"Park","year":"2022","journal-title":"Mol. Pharm."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Han, Y., Jones, T.W., Dutta, S., Zhu, Y., Wang, X., Narayanan, S.P., Fagan, S.C., and Zhang, D. (2021). Overview and Update on Methods for Cargo Loading into Extracellular Vesicles. Processes, 9.","DOI":"10.3390\/pr9020356"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.ymthe.2024.02.025","article-title":"Therapeutic potential of RNA-enriched extracellular vesicles: The next generation in RNA delivery via biogenic nanoparticles","volume":"32","author":"Muskan","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1038\/s41467-023-42365-5","article-title":"Adaptive design of mRNA-loaded extracellular vesicles for targeted immunotherapy of cancer","volume":"14","author":"Dong","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"114515","DOI":"10.1016\/j.jconrel.2025.114515","article-title":"A single extracellular vesicle-based platform supporting both RBD protein and mRNA vaccination against SARS-CoV-2","volume":"390","author":"Chung","year":"2026","journal-title":"J. Control. Release"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e70201","DOI":"10.1002\/jev2.70201","article-title":"Hybrid Extracellular Vesicles for Efficient Loading and Functional Delivery of mRNA","volume":"14","author":"Wang","year":"2025","journal-title":"J. Extracell. Vesicles"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e09636","DOI":"10.1002\/adfm.202509636","article-title":"Engineering Hybrid Extracellular Vesicles for Functional mRNA Delivery","volume":"36","author":"Louro","year":"2026","journal-title":"Adv. Funct. Mater."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1039\/D4BM01405G","article-title":"Hybrid lipid nanoparticles derived from human mesenchymal stem cell extracellular vesicles by microfluidic sonication for collagen I mRNA delivery to human tendon progenitor stem cells","volume":"13","author":"Lamparelli","year":"2025","journal-title":"Biomater. Sci."},{"key":"ref_66","first-page":"100428","article-title":"Engineered extracellular vesicles demonstrate altered endocytosis and biodistribution and have superior oral siRNA delivery efficiency compared to lipid nanoparticles","volume":"10","author":"Ding","year":"2025","journal-title":"Int. J. Pharm. X"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ymthe.2024.12.052","article-title":"Inverted HA-EV immunization elicits stalk-specific influenza immunity and cross-protection in mice","volume":"33","author":"Zhu","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"10858","DOI":"10.1021\/acsnano.5c13363","article-title":"Mosaic Inverted Hemagglutinin Extracellular Vesicle Vaccines Elicit Protective Systemic and Mucosal Immunity against Heterosubtypic Influenza Infection","volume":"20","author":"Zhu","year":"2026","journal-title":"ACS Nano"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"25526","DOI":"10.1021\/acsnano.5c08831","article-title":"Mature Dendritic Cell-Derived Extracellular Vesicles are Potent Mucosal Adjuvants for Influenza Hemagglutinin Vaccines","volume":"19","author":"Dong","year":"2025","journal-title":"ACS Nano"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41541-023-00760-5","article-title":"The advances of adjuvants in mRNA vaccines","volume":"8","author":"Xie","year":"2023","journal-title":"npj Vaccines"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"101427","DOI":"10.1016\/j.omtm.2025.101427","article-title":"mRNA-LNP vaccine strategies: Effects of adjuvants on non-parenchymal liver cells and tolerance","volume":"33","author":"Svensson","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"eaau0810","DOI":"10.1126\/science.aau0810","article-title":"Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity","volume":"367","author":"Wang","year":"2020","journal-title":"Science"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"35895","DOI":"10.1021\/acsami.3c05456","article-title":"Mucosal SARS-CoV-2 Nanoparticle Vaccine Based on Mucosal Adjuvants and Its Immune Effectiveness by Intranasal Administration","volume":"15","author":"Xiao","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"6053","DOI":"10.1038\/s41467-024-50234-y","article-title":"An intranasal nanoparticle STING agonist protects against respiratory viruses in animal models","volume":"15","author":"Leekha","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"123039","DOI":"10.1016\/j.biomaterials.2024.123039","article-title":"Lipid nanoparticles encapsulating both adjuvant and antigen mRNA improve influenza immune cross-protection in mice","volume":"317","author":"Wei","year":"2025","journal-title":"Biomaterials"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"eads1328","DOI":"10.1126\/sciimmunol.ads1328","article-title":"An Il12 mRNA-LNP adjuvant enhances mRNA vaccine-induced CD8 T cell responses","volume":"10","author":"Aunins","year":"2025","journal-title":"Sci. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41551-025-01347-2","article-title":"Author Correction: Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA","volume":"9","author":"Li","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"(2025). PEG alternatives for RNA therapeutics. Nat. Mater., 24, 1665.","DOI":"10.1038\/s41563-025-02408-2"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1038\/s41563-025-02381-w","article-title":"Making way for PEG alternatives","volume":"24","author":"Gao","year":"2025","journal-title":"Nat. Mater."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41563-024-02116-3","article-title":"High-density brush-shaped polymer lipids reduce anti-PEG antibody binding for repeated administration of mRNA therapeutics","volume":"24","author":"Xiao","year":"2025","journal-title":"Nat. Mater."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41563-025-02240-8","article-title":"Poly(carboxybetaine) lipids enhance mRNA therapeutics efficacy and reduce their immunogenicity","volume":"24","author":"Luozhong","year":"2025","journal-title":"Nat. Mater."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1080\/17435889.2025.2500917","article-title":"The benefits of emerging alternatives to PEG for lipid nanoparticle RNA delivery systems","volume":"20","author":"Berger","year":"2025","journal-title":"Nanomedicine"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e2302712","DOI":"10.1002\/adhm.202302712","article-title":"Poly(N-methyl-N-vinylacetamide): A Strong Alternative to PEG for Lipid-Based Nanocarriers Delivering siRNA","volume":"13","author":"Berger","year":"2024","journal-title":"Adv. Healthc. Mater."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"124695","DOI":"10.1016\/j.ijpharm.2024.124695","article-title":"Replacing poly(ethylene glycol) with RAFT lipopolymers in mRNA lipid nanoparticle systems for effective gene delivery","volume":"665","author":"Hassanel","year":"2024","journal-title":"Int. J. Pharm."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5800","DOI":"10.1038\/s41467-024-50087-5","article-title":"Enhancing cross-protection against influenza by heterologous sequential immunization with mRNA LNP and protein nanoparticle vaccines","volume":"15","author":"Dong","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.1038\/s41467-021-27063-4","article-title":"Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization","volume":"12","author":"Lapuente","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1038\/s41590-024-01951-5","article-title":"Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates","volume":"25","author":"Gagne","year":"2024","journal-title":"Nat. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"eadx0037","DOI":"10.1126\/sciadv.adx0037","article-title":"Conserved CD8 T cell vaccines without B cell epitopes drive robust protection against SARS-CoV-2 that is enhanced by intranasal boost","volume":"11","author":"Chen","year":"2025","journal-title":"Sci. Adv."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/7\/596\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:29:44Z","timestamp":1783348184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/7\/596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":88,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["vaccines14070596"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14070596","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]}}}